Search Result
| Isoforms Recommended: |
PIM1
|
Results for "
PIM1
" in MedChemExpress (MCE) Product Catalog:
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-N1950
-
|
Dinatin
|
Pim
|
Cancer
|
|
Hispidulin is a natural flavone with a broad spectrum of biological activities. Hispidulin is a Pim-1 inhibitor with an IC50 of 2.71 μM.
|
-
-
- HY-101126
-
TP-3654
4 Publications Verification
|
Pim
|
Cancer
|
|
TP-3654 is a second-generation Pim kinase inhibitor with Ki values of 5 and 42 nM for Pim-1 and Pim-3, respectively.
|
-
-
- HY-13287
-
|
|
Pim
Autophagy
Apoptosis
|
Cancer
|
|
SGI-1776 free base is an inhibitor of Pim kinases, with IC50s of 7 nM, 363 nM, and 69 nM for Pim-1, -2 and -3, respectively.
|
-
-
- HY-10371
-
Pim1/AKK1-IN-1
Maximum Cited Publications
12 Publications Verification
LKB1/AAK1 dual inhibitor
|
Pim
|
Cancer
|
|
Pim1/AKK1-IN-1 is a potent multi-kinase inhibitor with Kd values of 35 nM/53 nM/75 nM/380 nM for Pim1/AKK1/MST2/LKB1 respectively, and also inhibits MPSK1 and TNIK.
|
-
-
- HY-16576A
-
SMI-4a
1 Publications Verification
TCS-PIM-1-4a
|
Pim
|
Cancer
|
|
SMI-4a (TCS-PIM-1-4a) is a poten, selective, cell-permeable and ATP-competitive Pim-1 inhibitor with an IC50 of 24 μM and a Ki of 0.6 μM. SMI-4a also inhibits Pim-2 (IC50 of 100 μM), and does not significantly inhibit the other serine/threonine- or tyrosine-kinases. SMI-4a has anticancer activity [1].
|
-
-
- HY-18095
-
CX-6258
3 Publications Verification
|
Pim
|
Cancer
|
|
CX-6258 is a potent and kinase selective pan-Pim kinases inhibitor, with IC50s of 5 nM, 25 nM and 16 nM for Pim-1, Pim-2 and Pim-3, respectively [1].
|
-
-
- HY-15260
-
|
BMS-863233
|
CDK
|
Cancer
|
|
XL413 is a potent, selective and ATP competitive inhibitor of Cdc7, with an IC50 of 3.4 nM, and also shows potent effect with IC50s of 215, 42 nM on CK2, PIM1, respectively, and an EC50 of 118 nM on pMCM.
|
-
-
- HY-18086
-
|
SC 204330
|
Pim
|
Cancer
|
|
TCS PIM-1 1 (SC 204330) is a potent, selective and ATP-competitive Pim-1 kianse inhibitor with an IC50 of 50 nM, displays good selectivity over Pim-2 and MEK1/MEK2 (IC50s >20000 nM) [1].
|
-
-
- HY-19322B
-
|
LGH447 dihydrochloride
|
Pim
Apoptosis
|
Cancer
|
|
PIM447 dihydrochloride (LGH447 dihydrochloride) is a potent, orally available, and selective pan-PIM kinase inhibitor, with Ki values of 6, 18, and 9 pM for PIM1, PIM2, and PIM3, respectively. PIM447 dihydrochloride displays dual antimyeloma and bone-protective effects. PIM447 dihydrochloride induces apoptosis [1] .
|
-
-
- HY-147785
-
|
|
Pim
Caspase
Bcl-2 Family
Apoptosis
|
Cancer
|
|
Pim-1 kinase inhibitor 2 is a PIM-1 kinase inhibitor with a human IC50 of 0.63 μM. Pim-1 kinase inhibitor 2 exhibits high selectivity for cancer cells over normal cells. Pim-1 kinase inhibitor 2 induces apoptosis, increases active caspase-3 levels, upregulates BAX, downregulates Bcl-2, and elevates the Bax/Bcl-2 ratio. Pim-1 kinase inhibitor 2 suppresses cancer cell proliferation and induces cell cycle arrest. Pim-1 kinase inhibitor 2 can be used for the research of prostate carcinoma, hepatocellular carcinoma, and breast adenocarcinoma [1].
|
-
-
- HY-101947
-
|
PIM1/2 Kinase Inhibitor VI
|
Pim
|
Cancer
|
|
SMI-16a is a selective Pim kinase inhibitor with IC50 values of 0.15, 0.02 and 48 μM for Pim1, Pim2 and PC3 cells, respectively.
|
-
-
- HY-108605
-
|
|
Pim
|
Cancer
|
|
PIM1-IN-2 is a potent and ATP competitive Pim-1 inhibitor with a Ki of 91 nM. PIM1-IN-2 targets the ATP-binding kinase hinge region not by forming classical hydrogen bonds [1].
|
-
-
- HY-N4149
-
|
6-Hydroxyquercetin
|
Pim
|
Inflammation/Immunology
Cancer
|
|
Quercetagetin (6-Hydroxyquercetin) is a flavonoid [1]. Quercetagetin is a moderately potent and selective, cell-permeable pim-1 kinase inhibitor (IC50, 0.34 μM) . Anti-inflammatory and anticancer properties.
|
-
-
- HY-15260A
-
|
BMS-863233 monohydrochloride
|
CDK
|
Cancer
|
|
XL413 (BMS-863233) hydrochloride is a potent, selective and ATP competitive inhibitor of Cdc7, with an IC50 of 3.4 nM, and also shows potent effect with IC50s of 215, 42 nM on CK2, PIM1, respectively, and an EC50 of 118 nM on pMCM.
|
-
-
- HY-16976
-
|
|
Pim
|
Cancer
|
|
GDC-0339 is a potent, orally bioavailable and well tolerated pan-Pim kinase inhibitor, with Kis of 0.03 nM, 0.1 nM and 0.02 nM for Pim1, Pim2 and Pim3, respectively. GDC-0339 is discovered as a potential treatment of multiple myeloma [1] .
|
-
-
- HY-12830
-
|
|
Pim
|
Cancer
|
|
M-110 is a highly selective, ATP-competitive inhibitor of PIM kinases with a preference for PIM-3 (IC50=47 nM). M-110 inhibits PIM-1 and PIM-2 with similar IC50s of 2.5 μM. M-110 inhibits the proliferation of prostate cancer cell lines with IC50s of 0.6 to 0.9 μM [1].
|
-
-
- HY-19322
-
|
LGH447
|
Pim
Apoptosis
|
Cancer
|
|
PIM447 (LGH447) is a potent, orally available, and selective pan-PIM kinase inhibitor, with Ki values of 6, 18, and 9 pM for PIM1, PIM2, and PIM3, respectively. PIM447 displays dual antimyeloma and bone-protective effects. PIM447 induces apoptosis [1] .
|
-
-
- HY-12929
-
|
SU093
|
Pim
Apoptosis
|
Cancer
|
|
NSC756093 (SU093) is a GBP1:PIM1 interaction inhibitor. NSC756093 binds to GBP1-PIM1 with a Kd of 38 nM. NSC756093 suppresses proliferation, reduces migration, induces G1 phase cell-cycle arrest, and increases apoptotic cell death in ovarian cancer cells. NSC756093 reduces cellular proteasomal activity, induces accumulation of ubiquitinated proteins, and restrains tumor progression and lung metastasis in murine ovarian cancer xenograft models. NSC756093 increases sensitivity of prostate cancer cells to Docetaxel (HY-B0011) and sensitizes GBP1-overexpressing ovarian cancer cells to Paclitaxel (HY-B0015). NSC756093 can be used for the research of prostate cancer and ovarian cancer [1] .
|
-
-
- HY-18095A
-
|
|
Pim
|
Cancer
|
|
CX-6258 hydrochloride hydrate is a potent and kinase selective pan-Pim kinases inhibitor, with IC50s of 5 nM, 25 nM and 16 nM for Pim-1, Pim-2 and Pim-3, respectively [1].
|
-
-
- HY-111552
-
|
|
Pim
|
Cancer
|
|
PIM1-IN-1 is a potent and highly selective PIM1/3 inhibitor, with IC50s of 7, 5530 and 70 nM for PIM1, PIM2, and PIM3, respectively, inhibits the phosphorylation of BAD, a downstream target of PIM, with an EC50 of 262 nM. PIM1-IN-1 shows no obvious effect on FLT3 or hERG binding. Antiproliferative and anti-cancer activity [1].
|
-
-
- HY-120758
-
|
|
Pim
FLT3
Apoptosis
|
Cancer
|
SEL24-B489 is a potent, type I, orally active, dual PIM and FLT3-ITD inhibitor, with Kd values of 2 nM for PIM1, 2 nM for PIM2 and 3 nM for PIM3, respectively [1].
|
-
-
- HY-101870
-
|
INCB053914
|
Pim
|
Cancer
|
|
Uzansertib (INCB053914) is an orally active, ATP-competitive pan-PIM kinase inhibitor with IC50s of 0.24 nM, 30 nM, 0.12 nM for PIM1, PIM2, PIM3, respectively. Uzansertib has broad anti-proliferative activity against a variety of hematologic tumor cell lines [1].
|
-
-
- HY-101870B
-
|
INCB053914 phosphate
|
Pim
|
Cancer
|
|
Uzansertib (INCB053914) phosphate is an orally active, ATP-competitive pan-PIM kinase inhibitor with IC50s of 0.24 nM, 30 nM, 0.12 nM for PIM1, PIM2, PIM3, respectively. Uzansertib phosphate has broad anti-proliferative activity against a variety of hematologic tumor cell lines [1].
|
-
-
- HY-162006
-
|
|
Pim
Apoptosis
Autophagy
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Pim-1 kinase inhibitor 8 is a potent PIM-1 inhibitor with an IC50 value of 14.3 nM. Pim-1 kinase inhibitor 8 impedes cell proliferation and migration through PIM-1 inhibition and the induction of both apoptosis and autophagy. Pim-1 kinase inhibitor 8 inhibits solid tumor growth in Solid Ehrlich Carcinoma (SEC)-bearing mice. Pim-1 kinase inhibitor 8 can be used for breast and liver cancer research [1].
|
-
-
- HY-150731
-
|
|
Pim
|
Cancer
|
|
Pim-1 kinase inhibitor 3 (Compound H5) is a potent Pim-1 kinase inhibitor with an IC50 of 35.13 nM [1].
|
-
-
- HY-18095B
-
|
|
Pim
|
Cancer
|
|
CX-6258 hydrochloride is a potent and kinase selective pan-Pim kinases inhibitor, with IC50s of 5 nM, 25 nM and 16 nM for Pim-1, Pim-2 and Pim-3, respectively [1].
|
-
-
- HY-142696A
-
|
|
CDK
Pim
Apoptosis
|
Cancer
|
CDK6/PIM1-IN-1 (Compound 51) hydrochloride is an orally active and potent dual CDK6/PIM1 inhibitor with IC50 values of 39 and 88 nM, respectively. CDK6/PIM1-IN-1 hydrochloride inhibits CDK4 (IC50=3.6 nM). CDK6/PIM1-IN-1 hydrochloride significantly inhibits acute myeloid leukemia (AML) cell proliferation, arrest cell cycle at the G1 phase, and promote cell apoptosis. CDK6/PIM1-IN-1 exhibits potent anti-AML activity [1].
|
-
-
- HY-135906
-
|
|
Casein Kinase
ERK
Pim
DYRK
Apoptosis
|
Cancer
|
|
CK2/ERK8-IN-1 is a dual casein kinase 2 (CK2) (Ki of 0.25 µM) and ERK8 (MAPK15, ERK7) inhibitor with IC50s of 0.50 μM. CK2/ERK8-IN-1 also binds to PIM1, HIPK2 (homeodomain-interacting protein kinase 2), and DYRK1A with Kis of 8.65 µM, 15.25 µM, and 11.9 µM, respectively. CK2/ERK8-IN-1 has pro-apoptotic efficacy [1].
|
-
-
- HY-122665
-
|
|
MELK
DYRK
Pim
mTOR
CDK
GSK-3
RIP kinase
|
Cancer
|
|
HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC50 of 10.5 nM. HTH-01-091 also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and CLK2. HTH-01-091 can be uesd for breast cancer research [1].
|
-
-
- HY-W412264
-
|
|
Pim
|
Cancer
|
|
Pim-1/2 kinase inhibitor 1 is an orally active pim-1/2 kinase inhibitor. Pim-1/2 kinase inhibitor 1 blocks the ability of Pim kinases to phosphorylate peptides, and inhibits the pim protein kinase directed phosphorylation of 4E-BP1 and p27 Kip1. Pim-1/2 kinase inhibitor 1 can be used in study of cancer, especially prostate cancer [1].
|
-
-
- HY-142696
-
|
|
CDK
Pim
Apoptosis
|
Cancer
|
CDK6/PIM1-IN-1 is a potent and balanced dual CDK6/PIM1 inhibitor with IC50 values of 39 and 88 nM, respectively. CDK6/PIM1-IN-1 inhibits CDK4 (IC50=3.6 nM). CDK6/PIM1-IN-1 significantly inhibits acute myeloid leukemia (AML) cell proliferation, arrest cell cycle at the G1 phase, and promote cell apoptosis. CDK6/PIM1-IN-1 exhibits potent anti-AML activity [1].
|
-
-
- HY-P10042
-
|
|
Ribosomal S6 Kinase (RSK)
|
Others
|
|
S6K Substrate is a substrate for active protein kinases, including CLK2, MRCKalpha, MRCKbeta, p70S6K, ROCK1, ROCK2, RSK1, RSK3, PIM1 [1].
|
-
-
- HY-123983
-
|
|
Pim
DAPK
|
Cardiovascular Disease
|
|
HS56 is an ATP-competitive dual Pim/DAPK3 inhibitor with Ki values of 0.26, 0.208, 2.94, and ＞100 μM for DAPK3, Pim-3, Pim-1, and Pim-2, respectively. HS56 inhibits LC20 phosphorylation and smooth muscle contraction. HS56 decreases blood pressure in spontaneously hypertensive mice. HS56 can be used in research of hypertension [1].
|
-
-
- HY-143898
-
|
|
Pim
|
Cancer
|
|
PIM1-IN-4 (Compound 8) is a potent inhibitor of PIM1. PIM1-IN-4 reveals strong inhibition of five other enzymes, i.e., SGK-1, PKA, CaMK-1, GSK3β, and MSK1. PIM1-IN-4 has the potential for the research of cancer diseases [1].
|
-
-
- HY-115590
-
|
|
Pim
Caspase
Apoptosis
Necroptosis
PARP
NF-κB
|
Cancer
|
|
JP-11646 is a pan-PIM inhibitor with increased potency against PIM2 (IC50 = 0.5 nM). JP11646 is freely reversible and ATP non-competitive. JP-11646 results in a decrease of PIM1, 2, and 3 mRNA. JP-11646 can effectively inhibit cell viability in small cell lung cancer (SCLC) and large cell neuroendocrine carcinomas of the lung (LCNEC). JP-11646 can cause a decrease in p-4EBP-1 protein, increasing the cleavage of caspases while decreasing caspase-3. JP-11646 induces apoptosis or necroptosis in cells. JP-11646 leads to reductions in MYC paralogs. JP-11646 can be used for the study of SCLC, LCNEC, human acute leukemia (AML), multiple myeloma (MM), and triple-negative breast cancer (TNBC) [1] .
|
-
-
- HY-178443
-
|
|
Pim
Apoptosis
|
Cancer
|
|
Pim-1 kinase-IN-15 (Compound 15) is a highly potent and selective Pim-1 kinase inhibitor (IC50=0.212 μM). Pim-1 kinase-IN-15 induces tumor cell apoptosis and suppresses cell migration. Pim-1 kinase-IN-15 is promising for research of oncology, such as breast cancer [1].
|
-
-
- HY-178133
-
|
|
Pim
Apoptosis
Caspase
|
Cancer
|
|
Pim-1 kinase-IN-14 is a PIM-1 kinase inhibitor with an IC50 value of 94 nM. Pim-1 kinase-IN-14 shows broad-spectrum and high-efficiency anticancer activity against multiple human cancer cell lines, including liver cancer (HepG-2), colon cancer (Caco-2), myeloid leukemia (NFS-60), and prostate cancer (PC-3) cells. Pim-1 kinase-IN-14exerts its anticancer effects by inducing apoptosis and activating caspase 3/7. Pim-1 kinase-IN-14 can be used for the study of cancers associated with PIM-1 kinase overexpression [1].
|
-
-
- HY-143295
-
|
|
Pim
Apoptosis
|
Cancer
|
|
Pim-1 kinase inhibitor 1 is a Pim-1 kinase inhibitor with an IC50 of 0.11 μM for Pim-1 kinase. Pim-1 kinase inhibitor 1 shows anticancer activity to several cancer cell lines by promotes cell apoptosis. Pim-1 kinase inhibitor 1 can be used for the research of cancer [1].
|
-
-
- HY-162059
-
|
|
Pim
Apoptosis
Caspase
|
Cancer
|
|
Pim-1 kinase inhibitor 10 (compound 13a) is a both competitive and non-competitive inhibitor of PIM-1/2 kinase. Pim-1 kinase inhibitor 10 can induce cell apoptosis and exhibits anticancer activity. Pim-1 kinase inhibitor 10 also induces caspase 3/7 activation [1].
|
-
-
- HY-101783
-
|
|
Pim
|
Cancer
|
|
GNE-955 is a potent and orally active pan Pim kinase inhibitor with Kis of 0.018, 0.11, 0.08 nM for Pim1, Pim2, Pim3, respectively.
|
-
-
- HY-RS10548
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Pim1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pim1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Pim1 Mouse Pre-designed siRNA Set A
Pim1 Mouse Pre-designed siRNA Set A
-
- HY-164460
-
|
|
Pim
|
Cancer
|
|
AZD1897 is a PIM1, PIM2, and PIM3 inhibitor with IC50 values of less than 3 nM for these three PIM kinases. AZD1897 exhibits anticancer activity and synergistically inhibits the activity of acute myeloid leukemia (AML) cells in combination with Capivasertib (HY-15431). This synergistic inhibitory effect is achieved through the inhibition of the mTOR and MCL1 pathways [1] .
|
-
-
- HY-RS10549
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Pim1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Pim1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Pim1 Rat Pre-designed siRNA Set A
Pim1 Rat Pre-designed siRNA Set A
-
- HY-RS10547
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
PIM1 Human Pre-designed siRNA Set A contains three designed siRNAs for PIM1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
PIM1 Human Pre-designed siRNA Set A
PIM1 Human Pre-designed siRNA Set A
-
- HY-168071
-
|
|
Pim
|
Cancer
|
|
Pim-1 kinase inhibitor 11 (10f) is a PIM-1 inhibitor, with an IC50 of 0.18 μM. Pim-1 kinase inhibitor 11 (10f) exhibits anticancer activity. Pim-1 kinase inhibitor 11 (10f) induces apoptosis and arrests cell cycle progression [1].
|
-
-
- HY-156915
-
|
|
Pim
|
Inflammation/Immunology
Cancer
|
|
Pim-1 Kinase Inhibitor 13 (compound 10) is a Pim-1 kinase inhibitor with an IC50 of 4.41 μM. Pim-1 Kinase Inhibitor 13 can be utilized in immunology or cancer research [1].
|
-
-
- HY-163119
-
|
|
Pim
|
Cancer
|
|
Pim-1 kinase inhibitor 9 (compound 8b) is a selective inhibitor against Pim-1 kinase with IC50 value of 0.24 µM. Pim-1 kinase inhibitor 9 inhibits cell cycle of T47D at S phase. Pim-1 kinase inhibitor 9 reveals antitumor activity [1].
|
-
-
- HY-149976
-
|
|
Pim
|
Cancer
|
|
Pim-1 kinase inhibitor 4 (Compound 10f) is a Pim-1 kinase inhibitor (IC50: 17.01 nM). Pim-1 kinase inhibitor 4 also has antioxidant activity and inhibits DPPH. Pim-1 kinase inhibitor 4 induces apoptosis in PC-3 cell, and inhibits PC-3 cell growth with an IC50 of 16 nM. Pim-1 kinase inhibitor 4 can be used for research of prostate cancer [1].
|
-
-
- HY-147920
-
|
|
Pim
|
Cancer
|
|
PIM1-IN-6 (compound 5h) is a potent PIM-1 inhibitor, with an IC50 of 0.60 μM. PIM1-IN-6 shows the high cytotoxicity activity against HCT-116 and MCF-7 cells, with IC50 values of 1.51 and 15.2 μM, respectively [1].
|
-
-
- HY-149996
-
|
|
Pim
|
Cancer
|
|
Pim-1 kinase inhibitor 6 (Compound 4d) is a potent Pim-1 kinase inhibitor with IC50 value of 0.46 μM, and has significant cytotoxic effect on cancer cells [1].
|
-
- HY-149995
-
|
|
Pim
|
Cancer
|
|
Pim-1 kinase inhibitor 5 (Compound 4c) is a Pim-1 kinase inhibitor (IC50: 0.61 μM). Pim-1 kinase inhibitor 5 shows cytotoxicity against cancer cells, with IC50s of 6.95-20.19 μM for HepG2, MCF-7, PC3, and HCT-116 cells [1].
|
-
- HY-122665A
-
|
|
MELK
DYRK
Pim
mTOR
CDK
GSK-3
RIP kinase
|
Cancer
|
|
HTH-01-091 TFA is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC50 of 10.5 nM. HTH-01-091 TFA also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and CLK2. HTH-01-091 TFA can be uesd for breast cancer research [1].
|
-
- HY-143897
-
|
|
Pim
Apoptosis
|
Cancer
|
|
PIM1-IN-3 (Compound HL8) is a potent inhibitor of PIM1. PIM1-IN-3 shows selective inhibition for the PIM-1 enzyme. PIM1-IN-3 induces apoptosis efficiently in Colo320 cells. PIM1-IN-3 has the potential for the research of cancer diseases [1].
|
-
- HY-175277
-
|
|
Pim
NF-κB
Interleukin Related
|
Inflammation/Immunology
|
|
PIM1-IN-8 is a PIM1/p65 pathway inhibitor. PIM1-IN-8 suppresses the expression of α-SMA and collagen I in activated fibroblasts and blocks TGF-β induced migration. PIM1-IN-8 alleviates pulmonary fibrosis in a Bleomycin (BLM) (HY-17565A)-induced pulmonary fibrosis mice model. PIM1-IN-8 can be used for the study of idiopathic pulmonary fibrosis (IPF) [1].
|
-
- HY-174302
-
|
|
Pim
HDAC
PARP
Apoptosis
|
Cancer
|
|
PIM-1/HDAC-IN-2 is a robust PIM/HDAC inhibitor (IC50 = 0.11 μM in MV4-11cells), which exerts a synergistic antiproliferative effect through a dual mechanism of inhibiting PIM1 kinase and selectively inhibiting HDAC6. PIM-1/HDAC-IN-2 induces cell apoptosis. PIM-1/HDAC-IN-2 remarkably induces the cleavage of PARP, thereby initiating the arrest of the cell cycle in G1 phase and a reduction in S phase. PIM-1/HDAC-IN-2 demonstrates significant anticancer efficacyin the MV4-11 xenograft model without notable toxicity[1].
|
-
- HY-135816
-
|
|
Casein Kinase
Pim
|
Inflammation/Immunology
Cancer
|
|
CK2/PIM1-IN-1 is an inhibitor of CK2 and PIM1, with IC50s of 3.787 μM and 4.327 μM for CK2 and PIM1, respectively. CK2/PIM1-IN-1 is developed for the research of proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, vascular disorders, pathogenic infections and certain immunological disorders [1].
|
-
- HY-157404
-
|
|
Pim
|
Cancer
|
|
Pim-1/2 kinase inhibitor 2 (compound 5b) is a competitive PIM-1 and PIM-2 kinase inhibitor with IC50s of 1.31 μM and 0.67 μM, respectively. Pim-1/2 kinase inhibitor 2 shows in-vitro low cytotoxicity against normal human lung fibroblast Wi-38 cell line and potent in-vitro anticancer activity against myeloid leukaemia (NFS-60), liver (HepG-2), prostate (PC-3), and colon (Caco-2) cancer cell lines [1].
|
-
- HY-181125
-
|
|
Pim
Apoptosis
|
Cancer
|
|
Pim-1 kinase-IN-16 is a potent PIM-1 kinase inhibitor. Pim-1 kinase-IN-16 can inhibit cancer cells proliferation, induce necrosis and late apoptosis. Pim-1 kinase-IN-16 can be used for the research of cancer, such as prostate cancer, colon cancer, lung cancer [1].
|
-
- HY-13287A
-
-
- HY-N1950R
-
|
Dinatin (Standard)
|
Reference Standards
Pim
|
Cancer
|
|
Hispidulin (Standard) is the analytical standard of Hispidulin. This product is intended for research and analytical applications. Hispidulin is a natural flavone with a broad spectrum of biological activities. Hispidulin is a Pim-1 inhibitor with an IC50 of 2.71 μM.
|
-
- HY-147921
-
|
|
Pim
|
Cancer
|
|
PIM1-IN-7 (compound 6c) is a potent PIM-1 inhibitor, with an IC50 of 0.67 μM. PIM1-IN-7 shows the high cytotoxicity activity against HCT-116 and MCF-7 cells, with IC50 values of 42.9 and 7.68 μM, respectively [1].
|
-
- HY-173224
-
|
|
CDK
Pim
|
Cancer
|
|
CDK2/PIM1-IN-1 is an inhibitor of CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM) kinases. CDK2/PIM1-IN-1 induces apoptosis and reduces tumor-promoting TNF-α expression. CDK2/PIM1-IN-1 has antitumor activity [1].
|
-
- HY-RS07734
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
LONP1 Human Pre-designed siRNA Set A contains three designed siRNAs for LONP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
LONP1 Human Pre-designed siRNA Set A
LONP1 Human Pre-designed siRNA Set A
- HY-P10042A
-
|
|
Ribosomal S6 Kinase (RSK)
|
Others
|
|
S6K Substrate acetate is a substrate for active protein kinases, including CLK2, MRCKalpha, MRCKbeta, p70S6K, ROCK1, ROCK2, RSK1, RSK3, PIM1 [1].
|
-
- HY-156470
-
|
|
Trk Receptor
Anaplastic lymphoma kinase (ALK)
c-Kit
EGFR
Pim
Casein Kinase
Checkpoint Kinase (Chk)
CDK
Apoptosis
|
Cancer
|
|
Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that shows good enzyme inhibitory activity against TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2. Multi-kinase-IN-6 reveals antiproliferative activity against MCF7, HCT116 and EKVX with IC50 values of 3.36 μM, 1.40 μM and 3.49 μM, respectively. Multi-kinase-IN-6 shows cell cycle arrest at the G1/S phase and G1 phase in MCF7 and HCT116 cells with good apoptotic effect [1].
|
-
- HY-179098
-
|
|
Raf
c-Met/HGFR
Pim
EGFR
VEGFR
Apoptosis
|
Cancer
|
|
Multi-target kinase-IN-8 (3d) is an anti-cancer agent. Multi-target kinase-IN-8 exhibits inhibitory activity against various protein kinases (B-Raf V600E (IC50 = 0.078 µg/mL), c-Met (IC50 = 0.405 µg/mL), Pim-1 (IC50 = 1.053 µg/mL), EGFR WT (IC50 = 0.177 µg/mL), VEGFR-2 (IC50 = 0.275 µg/mL)). Multi-target kinase-IN-8 can induce cell cycle arrest and promote early and late apoptosis. Multi-target kinase-IN-8 is commonly used in cancer research [1].
|
-
- HY-155529
-
|
|
Pim
|
Cancer
|
|
FD1024 is PIM inhibitor (IC50s: 1.96, 38.9, 4.17 nM for PIM1, 2, 3). FD1024 can be used for research of acute myeloid leukemia. FD1024 has strong antiproliferative activity against the tested AML cell lines, with 0.16 μM, 0.12 μM, 1.05 μM, 1.39μM for EOL-1, MV-4-11, KG-1, MOLM-16 cells. FD1024 also has antitumor efficacy in mice [1].
|
-
- HY-143233
-
|
|
Pim
HDAC
Apoptosis
|
Cancer
|
|
PIM-1/HDAC-IN-1 (compound 4d) is a PIM-1 inhibitor, with an IC50 of 343.87 nM. PIM-1/HDAC-IN-1 has strong inhibitory activity and selectivity against HDAC 1 and HDAC 6, with IC50 values of 63.65 and 62.39 nM, respectively. PIM-1/HDAC-IN-1 exhibits apoptosis inducing potential in MCF-7 cell lines. PIM-1/HDAC-IN-1 shows pre-G1 apoptosis and cell cycle arrest at G2/M phase [1].
|
-
- HY-117744
-
|
|
Pim
|
Endocrinology
Cancer
|
|
NMS-P645 is a PIM1 inhibitor. NMS-P645 exhibits anti-proliferative activity when combined with GDC-0941 (HY-50094) in TMPRSS2/ERG positive and negative PCa cells. NMS-P645 can reverse PIM1-induced pro-survival signals in prostate cells. NMS-P645 can be studied in research on prostate cancer [1].
|
-
- HY-169670
-
|
|
Pim
CDK
GSK-3
Src
|
Cancer
|
|
Protein kinase inhibitor 13 (Compound I-90) is the inhibitor for protein kinase that exhibits inhibitory effects on kinases such as PIM-1, CDK-2, GSK-3 and SRC [1].
|
-
- HY-P1404
-
|
|
Pim
|
Cancer
|
|
R8-T198wt is a cell-permeable carboxyl-terminal p27 Kip1 peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase [1].
|
-
- HY-N4149R
-
|
6-Hydroxyquercetin (Standard)
|
Reference Standards
Pim
|
Inflammation/Immunology
Cancer
|
|
Quercetagetin (Standard) is the analytical standard of Quercetagetin. This product is intended for research and analytical applications. Quercetagetin (6-Hydroxyquercetin) is a flavonoid [1]. Quercetagetin is a moderately potent and selective, cell-permeable pim-1 kinase inhibitor (IC50, 0.34 μM) . Anti-inflammatory and anticancer properties.
|
-
- HY-W844558
-
|
|
Pim
CDK
GSK-3
Src
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Protein kinase inhibitor 11 (Compound I-96) is a protein kinase inhibitor that can inhibit the activity of PIM-1, CDK-2, GSK-3, and SRC. Protein kinase inhibitor 11 holds promise for research in cancer, immune disorders, and neurodegenerative diseases [1].
|
-
- HY-155717
-
|
|
Autophagy
Pim
|
Cancer
|
|
NDBM is a probe and binds to tumor-specific Pim-1 kinase, releases strong fluorescence, and produces cytotoxicity, thus achieving cell screening and killing effects. NDBM can specifically target lysosomes and sensitively respond to pH. NDBM can be used to track the pH changes in the intracellular environment under conditions of autophagy and external stimulation [1].
|
-
- HY-168479
-
|
|
Pim
|
Infection
Cancer
|
|
VB1080 (compound 12) is a potent PIM inhibitor with IC50 values of 69.5, 4996, 9.88 µM for PIM1, PIM2, PIM3, respectively. VB1080 shows cytotoxicity. VB1080 shows anthelmintic activity [1].
|
-
- HY-10371R
-
|
LKB1/AAK1 dual inhibitor (Standard)
|
Reference Standards
Pim
|
Cancer
|
|
Pim1/AKK1-IN-1 (Standard) is the analytical standard of Pim1/AKK1-IN-1 (HY-10371). This product is intended for research and analytical applications. Pim1/AKK1-IN-1 is a potent multi-kinase inhibitor with Kd values of 35 nM/53 nM/75 nM/380 nM for Pim1/AKK1/MST2/LKB1 respectively, and also inhibits MPSK1 and TNIK.
|
-
- HY-19322C
-
|
(1S,3R,5R)-LGH447 dihydrochloride
|
Pim
|
Cancer
|
|
(1S,3R,5R)-PIM447 (dihydrochloride) an PIM inhibitor extracted from patent US 20100056576 A1, compound example 72, has IC50 values of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3.
|
-
- HY-168517
-
|
|
Pim
Casein Kinase
Apoptosis
|
Cancer
|
|
PIM-1/CK2-IN-2 (compound 3aA) is a PIM-1/CK2 inhibitor. PIM-1/CK2-IN-2 can induce the mitochondrial apoptotic pathway in CCRF-CEM cells. PIM-1/CK2-IN-2 can be used in cancer research [1].
|
-
- HY-120561
-
|
|
Trk Receptor
IRAK
Pim
Apoptosis
|
Cancer
|
|
PC-046 is a multi-target inhibitor for tyrosine receptor kinase B (TrkB), IRAK-4 and Pim-1, with IC50 of 13.4 μM, 15.4 μM and 19.1 μM, respectively. PC-046 exhibits cytotoxicity against pancreatic cancer cell BxPC3 with IC50 of 7.5-130 nM. PC-046 induces apoptosis and arrests cell cycle at G2/M phase in BxPC3. PC-046 exhibits antitumor efficacy and exhibits good pharmacokinetic characteristics in mice [1].
|
-
- HY-101947R
-
|
PIM1/2 Kinase Inhibitor VI (Standard)
|
Reference Standards
Pim
|
Cancer
|
|
SMI-16a (Standard) is the analytical standard of SMI-16a (HY-101947). This product is intended for research and analytical applications. SMI-16a is a selective Pim kinase inhibitor with IC50 values of 0.15, 0.02 and 48 μM for Pim1, Pim2 and PC3 cells, respectively.
|
-
- HY-101126R
-
|
|
Pim
Reference Standards
|
Cancer
|
|
TP-3654 (Standard) is the analytical standard of TP-3654 (HY-101126). This product is intended for research and analytical applications. TP-3654 is a second-generation Pim kinase inhibitor with Ki values of 5 and 42 nM for Pim-1 and Pim-3, respectively.
|
-
- HY-182957
-
|
|
MNK
Pim
Apoptosis
Caspase
Eukaryotic Initiation Factor (eIF)
PARP
c-Myc
|
Cancer
|
|
MNK/PIM-IN-2 is a Mnk/Pim kinase inhibitor with an IC50 of 32 nM for Mnk1, 3 nM for Mnk2, and 37 nM for Pim1. MNK/PIM-IN-2 reduces the levels of p-eIF4E and p-4EBP1. MNK/PIM-IN-2 induces cell cycle arrest, apoptosis (apoptosis) and exerts antiproliferative effects in leukemia cells. MNK/PIM-IN-2 can be used in studies related to leukemia [1].
|
-
- HY-186146A
-
|
SGI-1776-cis-VHL-02
|
Drug Isomer
Pim
c-Myc
Apoptosis
|
Cancer
|
|
SGI-1776-VHL-02-epimer (SGI-1776-cis-VHL-02) is an epimer control compound of with SGI-1776-VHL-02 (HY-186146). SGI-1776-VHL-02-epimer has an inverted stereocenter in the critical hydroxyl-proline group in the VHL ligand. SGI-1776-VHL-02-epimer cannot trigger the VHL E3 ligase complex and does not degrade PIM1 [1].
|
-
- HY-18088
-
|
|
Pim
|
Cancer
|
|
PIM-IN-4 is a Pim kinase inhibitor with Ki values of 2, 3, and 0.5 nM against Pim-1, 2, 3, respectively. PIM-IN-4 blocks the phosphorylation of the pro-apoptotic protein Bad. PIM-IN-4 inhibits the growth of leukemia cells. PIM-IN-4 is applicable for leukemia-related research [1].
|
-
- HY-186146
-
|
|
Pim
c-Myc
Apoptosis
|
Cancer
|
|
SGI-1776-VHL-02 is a stereoselective PIM PROTAC degrader. SGI-1776-VHL-02 promotes the ubiquitination and degradation of PIM1, PIM2 and PIM3. SGI-1776-VHL-02 downregulates c-myc protein levels, induces Apoptosis. SGI-1776-VHL-02 has anti-cancer activity against prostate cancer. SGI-1776-VHL-02 can be used in studies related to prostate cancer [1].
|
-
- HY-182293
-
|
|
Btk
Src
BMX Kinase
FLT3
Pim
|
Inflammation/Immunology
Cancer
|
|
BTK-IN-48 is a BTK inhibitor with an IC50 of 1.14 μM. BTK-IN-48 inhibits recombinant BTK and c-Src, and exerts moderate inhibitory effects on LCK, BMX/ETK, FLT3 and PIM1. BTK-IN-48 can be used in the research of B-cell malignancies and autoimmune diseases [1].
|
-
- HY-181925
-
|
|
Apoptosis
Pim
mTOR
|
Cancer
|
|
FD2024 is a pan-PIM kinase inhibitor with IC50 values of 0.17 nM, 1.86 nM, and 0.38 nM against PIM-1, PIM-2, and PIM-3, respectively. FD2024 induces cell apoptosis. FD2024 inhibits the phosphorylation of mTOR, p70S6K, S6, 4EBP1, and BAD proteins. FD2024 exhibits anti-acute myeloid leukemia activity. FD2024 can be used in studies related to acute myeloid leukemia [1].
|
-
- HY-101870BR
-
|
INCB053914 phosphate (Standard)
|
Reference Standards
Pim
|
Cancer
|
|
Uzansertib phosphate (Standard) is the analytical standard of Uzansertib phosphate (HY-101870B). This product is intended for research and analytical applications. Uzansertib (INCB053914) phosphate is an orally active, ATP-competitive pan-PIM kinase inhibitor with IC50s of 0.24 nM, 30 nM, 0.12 nM for PIM1, PIM2, PIM3, respectively. Uzansertib phosphate has broad anti-proliferative activity against a variety of hematologic tumor cell lines [1].
|
-
- HY-171744
-
|
|
Casein Kinase
|
Cancer
|
|
CX-5279 is an efficient and selective CK2 inhibitor with IC50 values for nCK2 and CK2α of 2.73 and 0.91 nM, respectively. CX-5279 is sensitive to mutations at Val66, Ile174, and V66I174AA, with IC50 values of 13.8, 12.5, and 23.35 nM, respectively. CX-5279's inhibitory activity against PIM1 is very weak, with a IC50 value of 8.52 μM. CX-5279 exhibits anti-proliferative activity in various cancer cell lines. CX-5279 can be used for research on cancers such as pancreatic cancer and leukemia [1].
|
-
- HY-122670
-
|
|
Pim
Apoptosis
AMPK
DYRK
STAT
MDM-2/p53
|
Cancer
|
|
VS-II-173 is a pan-Pim kinase inhibitor with IC50 values of 0.07 μM and 0.02 μM for Pim1 and Pim3, respectively, and a residual activity of 46% for Pim2 at 1 μM. VS-II-173 also inhibits kinases such as HIPK2, PRK2, RSK1, DYRK1a and AMPKα1, selectively inhibiting acute myeloid leukemia (AML) cells with significantly lower toxicity to non-malignant cells (EC50 > 30 μM). VS-II-173 weakens the phosphorylation of substrates such as Stat5 (Y694), MDM2 (S166), Bad (S112), and 4E-BP1 (T37/46) by inhibiting Pim kinase-mediated signaling pathways, blocking pro-survival signals in AML cells and inducing apoptosis. VS-II-173 synergistically enhances anti-AML activity when combined with Daunorubicin (HY-13062A). VS-II-173 can be used in AML research, especially for AML with FLT3-ITD mutations and NPM1 mutations [1] .
|
-
- HY-183611
-
|
|
Bacterial
Interleukin Related
TNF Receptor
|
Infection
|
|
LPZ-51 is a Vibrio β-lactam resistance sensor kinase (VbrK) inhibitor with a Ki value of 1.09 μM. LPZ-51 inhibits blaA gene expression at the transcriptional level by blocking the kinase activity of VbrK, reduces β-lactamase synthesis, and does not affect bacterial growth. LPZ-51 acts synergistically with β-lactam antibiotics. LPZ-51 decreases bacterial load, alleviates intestinal inflammation, and improves survival rate in zebrafish infection models. LPZ-51 can be used in studies related to Vibrio parahaemolyticus infection [1].
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10042
-
|
|
Ribosomal S6 Kinase (RSK)
|
Others
|
|
S6K Substrate is a substrate for active protein kinases, including CLK2, MRCKalpha, MRCKbeta, p70S6K, ROCK1, ROCK2, RSK1, RSK3, PIM1 [1].
|
-
- HY-P10042A
-
|
|
Ribosomal S6 Kinase (RSK)
|
Others
|
|
S6K Substrate acetate is a substrate for active protein kinases, including CLK2, MRCKalpha, MRCKbeta, p70S6K, ROCK1, ROCK2, RSK1, RSK3, PIM1 [1].
|
-
- HY-P1404
-
|
|
Pim
|
Cancer
|
|
R8-T198wt is a cell-permeable carboxyl-terminal p27 Kip1 peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase [1].
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Recombinant Proteins Recommended: |
|
| Cat. No. |
Compare |
Product Name |
Species |
Source |
Image |
Compare Products
|
| Products |
|
| Cat. No. |
|
| Species |
|
| Source |
|
| Tag |
|
| Accession |
|
| Gene ID |
|
| Molecular Weight |
|
| Purity |
|
| Endotoxin Level |
|
| Biological Activity |
|
| Appearance |
|
| Formulation |
|
| Storage & Stability |
|
| Shipping |
|
| Free Sample |
Yes
No
|
| Size |
* This product has been "discontinued".
Optimized version of product available:
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-RS10548
-
|
|
|
siRNAs
Mouse Pre-designed siRNA Sets
|
|
Pim1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pim1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS10549
-
|
|
|
siRNAs
Rat Pre-designed siRNA Sets
|
|
Pim1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Pim1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS10547
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
PIM1 Human Pre-designed siRNA Set A contains three designed siRNAs for PIM1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS07734
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
LONP1 Human Pre-designed siRNA Set A contains three designed siRNAs for LONP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
